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Abstract To evaluate metrics that describe changes in
apparent diffusion coefficient (ADC) and to examine their
association with clinical outcome for patients with newly
diagnosed GBM who were participating in a Phase II
clinical trial of treatment with radiation (RT), temozolo-
mide, erlatonib and bevacizumab. Thirty six patients were
imaged after surgery but prior to therapy and at regular
follow-up time points. The following ADC metrics were
evaluated: (1) histogram percentiles within the T2-hyper-
intense lesion (T2L) at serial follow-ups; (2) parameters
obtained by fitting a two-mixture normal distribution to the
histogram within the contrast-enhancing lesion (CEL) at
baseline; (3) parameters obtained using both traditional and
graded functional diffusion maps within the CEL and T2L.
Cox Proportional Hazards models were employed to assess
the association of the ADC parameters with overall sur-
vival (OS) and progression-free survival (PFS). A lower
ADC percentile value within the T2L at early follow-up
time points was associated with worse outcome. Of
particular interest is that, even when adjusting for clinical
prognostic factors, the ADC10% within the T2L at 2 months
was strongly associated with OS (p \ 0.001) and PFS
(p \ 0.007). fDM metrics showed an association with OS
and PFS within the CEL when considered by univariate
analysis, but not in the T2L. Our study emphasizes the
value of ADC metrics obtained from the T2L at the post-
RT time point as non-invasive biomarkers for assessing
residual tumor in patients with newly diagnosed GBM
being treated with combination therapy that includes the
anti-angiogenic agent bevacizumab.
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Introduction
Bevacizumab is a humanized monoclonal VEGF-blocking
antibody that has been shown to normalize vascular per-
meability and regulate angiogenesis in patients with glio-
blastoma (GBM). Although it has been shown to reduce the
volume of the contrast enhancing lesion (CEL) on post-
Gadolinium T1-weighted MR images and to provide
improved time to progression in patients with recurrent
disease [1–3], recent Phase II and Phase III clinical trials
indicated that it is ineffective at extending overall survival
for patients with newly diagnosed GBM [4–7]. With a
growing number of studies providing evidence for
increased tumor invasiveness following treatment failure in
patients receiving bevacizumab [8], it is important to
identify at an early stage which patients are benefiting from
anti-angiogenic therapies, as opposed to treating all
patients in the same manner. Monitoring the effectiveness
of bevacizumab is challenging using conventional
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measures of response to therapy because reductions in the
CEL may be due to an anti-permeability effect rather than a
reduction in bulk tumor [9], which is commonly referred to
as ‘‘pseudoresponse’’ [10, 11]. Differentiation of non-
enhancing tumor within the T2L from edema or gliosis is
important for effectively monitoring response to bev-
acizumab and similar anti-angiogenic agents.
The apparent diffusion coefficient (ADC) is a metric that
characterizes the random motion of water molecule protons
at a microscopic level and may provide valuable insights to
tumor physiology. Decreases in ADC have been proposed
as a non-invasive measure of tumor cellularity and
increases in ADC to reflect a breakdown of tissue archi-
tecture [12–16]. A number of different strategies have been
proposed to define metrics in predicting clinical outcome
and monitoring response to therapy following treatment
with bevacizumab. These include parameters derived from
the histogram of ADC values within the anatomic lesion at
a single time point [17–19], and from functional diffusion
maps (fDMs) that evaluate serial changes in ADC on a
pixel by pixel basis [20–26]. For patients with recurrent
GBM being treated with bevacizumab, low values in the
pretreatment ADC histogram from the CEL that were fit to
a two normal distribution mixture curve were found to be
associated with poor outcome [17, 18], but in the up-front
setting low ADC was found to be associated with signifi-
cantly longer PFS [19]. When fDM analysis was used in
patients with recurrent GBM [25, 26], prior studies showed
that the volumes of tissue within the CEL and T2L that had
reduced ADC values between baseline and early post-
treatment scans were associated with PFS and OS.
Although these initial results indicate that ADC metrics
may be helpful in predicting treatment effectiveness for
patients with recurrent GBM, their utility has not yet been
fully explored for combination treatments that are being
applied in an upfront setting. Obtaining a detailed under-
standing of how to interpret early changes in these param-
eters and integrate them into criteria used for assessing
treatment response could have a significant impact on
patient care. The purpose of this study was to evaluate the
association of ADC metrics with clinical outcomes for
patients with newly diagnosed GBM who were participating
in a Phase II clinical trial that included bevacizumab.
Materials and methods
Patient population
A total of 151 MR scans that include diffusion weighted
imaging (DWI) were obtained from 36 patients with newly
diagnosed GBM who were participating in a Phase II
clinical trial during the period between January 9, 2009 and
April 3, 2012 (29 scans at baseline, 25 patients had com-
plete serial scans from baseline until progression). All
patients had pathologically confirmed GBM, a Karnofsky
Performance Score (KPS) of at least 60 and had undergone
prior biopsy (five patients) or surgical resection (10 gross-
total and 21 sub-total) but no other prior therapy. Patient
age ranged from 21 to 76 years, with a median of 52 years.
Treatment included external beam radiation therapy to an
average dose of 60 Gy and was delivered to the tumor site
in 2-Gy fractions over a 6-week period. The protocol called
for temozolomide to be given at a daily dose of 75 mg/m2,
during radiation therapy and at 200 mg/m2 for 5 days every
28 days afterwards, for erlotinib to be given daily both
during and after radiation, and for bevacizumab to be given
at a dose of 10 mg/kg IV every 2 weeks, starting at
approximately 2 weeks into radiation therapy [5]. All
patients participating in this study gave informed consent
according to the guidelines of our institutional review
board. Progression was determined based on the recently
defined RANO criteria [10].
MR imaging and post-processing
All scans were obtained using a 3T GE MR scanner. Time
points selected for study were at baseline (post-surgical
resection and prior to therapy), 1 month (mid-RT), 2 months
(post-RT) and every 2 months thereafter until presumed
tumor progression (up to a maximum of 14 months). Stan-
dard anatomical MR imaging included axial T2-weighted
fluid attenuated inversion recovery (FLAIR) images and pre-
and post-contrast T1-weighted spoiled gradient echo
(SPGR). DWI were acquired with b = 1,000 (dir = 6,
NEX = 4) and ADC maps were calculated using in-house
developed software. CEL regions were manually defined on
the coregistered post-contrast T1 SPGR images at each
available time point. Any hyperintense signal that was also
present on the pre-contrast T1 images was assumed to be
indicative of acute blood products and was excluded. The
T2L regions were segmented based on the hyper-intensity
region of FLAIR images using a semi-automatic region-
growing segmentation tool [27]. The resection cavity was
excluded from all ROIs.
Histogram analysis within the T2L and CEL
In regions of interest corresponding to T2Ls at time points
up to 8 months after the start of treatment, ADC histograms
followed an approximately normal distribution and were
characterized using percentile values (Fig. 1a). In this case
the 10th and 50th percentiles were chosen for subsequent
analysis to represent regions with more aggressive tumor.
At baseline, histograms of the ADC within the CEL were
also fit with a 2-mixture normal distribution (Fig. 1b).
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Mean values for the lower peak (ADCL) and the lower
curve proportion (LCP) were calculated in the manner
proposed by Pope et al. [17].
Functional diffusion map
For fDM analysis, ADC maps at baseline and 2 months
were co-registered using an affine registration with 12 of
freedom to ensure adequate alignment (http://www.fmrib.
ox.ac.uk/fsl/). Voxel-wise subtraction was performed
between 2 months and baseline ADC maps. Both tradi-
tional fDMs (Fig. 1c) [20] and graded fDMs (Fig. 1d) [25]
were generated. Due to the fact that our data were acquired
at a field strength of 3T than 1.5T as was used for these
earlier studies, a set of new thresholds were generated in
the same way as described in the literature [21, 24, 25]. For
each patient, the volume of tissue showing decreased ADC
(VolDADC), as well as the normalized volume showing
decreased ADC within the CEL and T2L (%VolDADC,
which was normalized against the overlapping lesion vol-
ume), were calculated.
Statistical analysis
Both univariate and multivariate Cox Proportional Hazards
(CoxPH) model with covariates of baseline KPS, age, and
extent of resection (0-biopsy, 1-subtotal, 2-grosstotal) were
employed to evaluate the relationship of the fitted param-
eters to progression-free survival (PFS) and overall sur-
vival (OS), landmarked from the scan date of the diffusion
parameters. In the case of no progression or death, the
event time was censored at the date of last contact. Clas-
sification and regression tree (CART) analysis was utilized
to determine the cut-off for dichotomizing the fitted
parameters [28]. Kaplan–Meier survival curves for each
subgroup determined by the CART split points were
compared using a log-rank test. Owing to the exploratory
nature of the study, no formal adjustment of type I error
was undertaken. In all cases, p \ 0.05 was considered
statistically significant (Matlab 2012a).
Results
Clinical
Median OS was 86.1 weeks with nine patients censored
and median PFS was 56.1 weeks with four patients cen-
sored for the 36 patients considered in this analysis, which
is consistent with our recent report on a larger population
study [5]. At the time of progression, 23 patients had
enhancing progressive disease, 11 patients had non-
enhancing progressive disease with only enlarged FLAIR
lesion volume, and two patients died before imaging fol-
low-up. Of the baseline clinical factors (KPS, age, gender
and extent of resection), only the extent of resection was
significantly associated with OS (Univariate, p \ 0.002,
HR = 0.285, 95 % CI = 0.134–0.608) and PFS (Univari-
ate, p \ 0.006, HR = 0.366, 95 % CI = 0.179–0.748).
Volumes of anatomic lesions
Table 1 lists the median and range of T2L and CEL vol-
umes at different time points. There was a noticeable
reduction at 1 and 2 months in the volumes of both CEL
and T2L. When considered as single variable, the volumes
Fig. 1 Illustration of methods for analyzing ADC: a Percentile
values extracted from the histogram of ADC values in the T2L. b 2-
mixture normal distribution fitting on ADC histograms in CEL.
c Traditional fDMs within the CEL overlaid on a T1 post-contrast
image at 2 months with scatter plot of the distribution of ADC
changes for the entire CEL. d Graded fDMs within the T2L overlaid
on a FLAIR image at 2 months with scatter plot of the distribution of
ADC changes for the entire T2L
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of the CEL at 1 and 2 months were associated with OS
(p \ 0.003, HR = 1.22 at 1 month; p \ 0.03, HR = 1.37
at 2 months) and PFS (p \ 0.03, HR = 1.11 at 1 month;
p \ 0.02, HR = 1.38 at 2 months). When adjusted for
clinical factors these associations were no longer signifi-
cant. The volumes of the T2L were not associated with OS
or PFS.
Histogram analysis
Within the T2L, the CoxPH model coefficients showed a
significant association for values of ADC10% and ADC50%
with OS and PFS (Table 2). A lower ADC percentile value
within the T2L indicated a poorer prognosis. The ADC10%
at 2 months (post-RT) was associated with PFS (univariate
CoxPH, p \ 0.03, HR = 0.52, 95 % CI = 0.29–0.93) and
OS (univariate CoxPH, p \ 0.01, HR = 0.37, 95 %
CI = 0.18–0.79). Adjusting for baseline KPS, age, extent
of resection, Cox regression analysis confirmed that lower
ADC10% within T2L at 2 months is still a risk factor for OS
(multivariate CoxPH, p \ 0.001, HR = 0.11, 95 %
CI = 0.03–0.41) and PFS (multivariate CoxPH, p \ 0.007,
HR = 0.31, 95 % CI = 0.13–0.72). Serial ADC percentile
changes of two age-matched patients who both had large
T2L at baseline are shown in Fig. 2. One patient pro-
gressed early and the other was stable and completed
therapy after being on treatment for 12 months. T2L and
ADC were significantly reduced in both cases immediately
following onset of therapy (Fig. 2a). At post-RT, T2L
volumes were comparable for both patients, but ADC
percentage values were much lower in the patient who
progressed early than the patient who was stable (Fig. 2b).
Figure 2c shows profiles of ADC histograms within T2L
and CEL over time.
A cutoff value of 853 lm2/s at the 2 month time point
was determined by CART analysis to differentiate patients
into two groups based on OS (log-rank, p = 0.00048)
(Fig. 3a), and a cutoff value of 853 lm2/s based on PFS
(log-rank, p = 0.02) (Fig. 3b). The mean and standard
Table 1 Volume for Anatomic Lesions [median (min–max) in cc]
Baseline 1 month 2 months 4 months 6 months 8 months
T2L 30.07 (1.71–142.60) 23.52 (1.51–140.42) 9.55 (0.05–41.64) 10.64 (0.28–43.55) 13.72 (0.37–46.35) 14.93 (0.12–44.17)
CEL 3.12 (0.19–21.94) 1.22 (0–17.65) 1.08 (0–7.2) 0.08 (0–3.13) 0.12 (0–1.93) 0.03 (0–4.02)
Table 2 Summary of multivariate CoxPH results with adjustment for KPS, age and extent of resection
Type Parameters
considered
Time point OS PFS
p value HR p value HR
Lesion size VolCEL (cc) BL 0.315 0.95 [0.87 1.05] 0.900 0.99 [0.92 1.08]
2mos 0.301 1.23 [0.83 1.81] 0.201 1.26 [0.89 1.79]
VolT2L (cc) BL 0.431 0.99 [0.98 1.01] 0.837 1.00 [0.99 1.15]
2mos 0.326 1.03 [0.97 1.10] 0.421 1.02 [0.97 1.07]
Histogram—
2-mixture normal fitting





BL 0.116 0.77 [0.55 1.07] 0.032* 0.69 [0.50 0.97]
1mos 0.188 0.54 [0.21 1.36] 0.014* 0.39 [0.18 0.83]
2mos 0.001* 0.11 [0.03 0.41] 0.007* 0.31 [0.13 0.72]
4mos 0.005* 0.43 [0.23 0.78] 0.024* 0.54 [0.32 0.92]
ADC50% 4mos 0.011* 0.61 [0.42 0.89] 0.045* 0.73 [0.54 0.99]
Traditional fDM in T2L VolDADC\-250
(cc)
BL-1mos 0.927 0.99 [0.82 1.20] 0.963 1.00 [0.84 1.20]
BL-2mos 0.552 1.13 [0.75 1.70] 0.603 1.09 [0.78 1.54]
Graded fDM in T2L Vol250\DADC\-180 BL-1mos 0.489 0.486 [0.06 3.76] 0.577 0.63 [0.13 3.16]
BL-2mos 0.347 2.36 [0.39 14.19] 0.481 1.65 [0.41 6.71]
*p \ 0.05
cFig. 2 Comparison of serial displays for two patients (left—pro-
gressed early, right—completed therapy without signs of progression)
who both had large T2L at baseline. T2L and ADC were significantly
reduced in both patients immediately following onset of therapy. At
post-RT, residual T2Ls were comparable for both patients, but ADC
percentage values were much lower in the patient who progressed
early than the patient who was stable. a ADC and FLAIR images at
baseline, 1 and 2 months. b Serial display of ADC percentiles and
lesion sizes. (PG progression, CT completed therapy, D deceased.).
c Serial display of ADC histograms in T2L and CEL lesions
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deviation for ADC10% over time for each split group is
shown in Fig. 3c. At baseline, no parameters from the
2-mixture normal fitting were found to be associated with
either OS or PFS (p [ 0.1).
fDM
The traditional fDM technique typically applies a single
DADC threshold to classify voxels into increasing or
decreasing ADC. The 95 % confidence interval for defin-
ing normal-appearing white and grey matter was 250 lm2/s
for our protocol. For graded fDMs, the 95 % confidence
interval for defining normal-appearing white matter was
180 lm2/s for our data set.
Within the CEL, the recommended minimum overlap-
ping CEL volume that should be considered is 4 cc for
traditional fDM [20]. In this study, due to the strong anti-
angiogenic effect, none of our patients had an overlapping
CEL larger than 4 cc. Without consideration of this crite-
ria, the traditional fDM and graded fDM analyses within
the CEL provided parameters that were associated with OS
and PFS (VolDADC\-250 with OS, p \ 0.003; HR = 9.52;
Vol-250\ADC\-180 with OS, p \ 0.03, HR = 15509; with
PFS p \ 0.03, HR = 23775). However, these were not
significant when adjusting for clinical factors. Within the
T2L, none of these parameters were found to be associated
with OS or PFS (Table 2).
Discussion
Although bevacizumab has been shown to reduce the
volume of the contrast enhancing and T2 lesions after the
initiation of therapy, the highly variable response and
limited improvement in OS times highlight the need for
identifying alternative parameters that can more accurately
predict treatment outcomes. Diffusion imaging techniques
are dependent on the microscopic structure of tissue, and
are sensitive to cell density and necrosis as well as vaso-
genic edema. It is for this reason that analysis of the ADC
maps has been proposed as a method for providing infor-
mation about the properties of both enhancing and non-
enhancing tumor.
Consistent with previous report for patients treated with
bevacizumab [1–4], there were reductions in the volumes
of the CEL and T2L at 1 and 2 month follow-up scans
(Table 1), and the CEL volume was associated with sur-
vival as a univariate variable [29]. However, this associa-
tion was no longer significant when adjusting for clinical
factors, suggesting that the CEL volume does not add value
in addition to clinical factors in relation to survival. We
would like to note that due to the strong anti-leakage effect
of bevacizumab, over half patients demonstrated CEL
volume \1 cc at 2 month, and 1/3 patients had non-
enhancing progressive disease. All these motivated us to
look more closely at the T2L as the region of interest for
imaging biomarkers.
Regions within T2L with low ADC values are thought to
correspond to regions of higher cellularity, while regions
with increased ADC to correspond to vasogenic edema
[32–34]. Both of these opposing effects are present within
the tumor microenvironment and may therefore counteract
each other. In tumors being actively treated with bev-
acizumab, vasogenic edema is more effectively controlled
[30], resulting in a reduction in the volume of the T2L and
lower ADC values that may more closely reflect the cel-
lularity of the tumor. Our results support this hypothesis by
indicating that lower ADC percentiles within the T2L at
2 months time window were significant risk factors for
both PFS and OS. Two factors that could influence ADC
Fig. 3 Stratification of patients based on CART analysis of ADC10%
in T2L at 2 months. a Kaplan–Meier curves for each group when split
on CART threshold at 2 months for OS with ADC10%\ 853 lm
2/s in
dash line (12 patients), ADC10% [853 lm
2/s in solid line (13
patients). b Kaplan–Meier curves for each group when split on CART
threshold at 2 months for PFS with ADC10%\853 lm
2/s in dash line
(12 patients), ADC10% [853 lm
2/s in solid line (13 patients). c The
mean and standard deviation for ADC10% over time for each CART
split group
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values in the earlier and later time window and confound
the interpretation of the data are ischemia that results from
the surgical resection and RT-induced edema. Regions of
ischemia occur around the resection cavity may result in
temporarily reduced ADC values that typically return to
normal within 90 days [31]. Regions of reduced ADC that
are observed during this early time frame should therefore
be interpreted with caution, as they may be confused with
recurrent tumor. In the later time frame (e.g. post-4mon),
increases in edema that occur during RT may result in
higher ADC values, which could mask the presence of
tumor. With bevacizumab, the confounding effects from
surgery and during RT appear to have resolved at 2 month,
so that the ADC values provided a more accurate repre-
sentation of residual tumor. At subsequent time points,
reactive edema associated with growing tumor may result
in elevated ADC (Fig. 3c). Another potential confounding
factor is gelatinous necrosis, which could cause persistent
restricted diffusion in bevacizumab treated patients [35–
37]. Caution must be exerted in interpreting restricted
diffusion because it has been reported that patients who
demonstrated such bevacizumab caused necrosis had
longer survival [35]. The average time of detecting such
necrosis with diffusion was 8 months, therefore it is unli-
kely to have developed by the 2 month follow-up in our
study (6 weeks into bevcizumab). We hypothesize that it is
for these reasons that the 2 months (post-RT) time point
appeared to be the best time point for using ADC to assess
residual tumor.
Although previous studies have shown that the two
normal distribution mixture curve analysis of pre-surgery
ADC histograms in the CEL can predict response to bev-
acizumab for patients with newly diagnosed GBM [19], we
were unable to detect an association for our patient popu-
lation. This may have been due to our baseline data having
been post-surgery and therefore lacking information about
the resected tumor and/or being influenced by surgically-
induced ischemia.
The fDM analysis was developed to examine voxel-wise
changes in ADC in the patient over time. Our results
showed that the fDM analysis of higher volumes of tissue
within the CEL that showed decreased ADC were associ-
ated with worse PFS and OS when considered without
adjustment for clinical factors. While this may be a less
sensitive metric than others, the finding is consistent with
areas of reduced diffusion corresponding to more cellular
tumor and hence inferring a worse outcome. The global
reduction in ADC metrics that we observed within the T2L
is likely to be due to reabsorption of edema after treatment.
Despite the promising results obtained in this study
using fDM analysis, there are limitations that should be
taken into account in patients treated with bevacizumab in
the up-front setting. First, the CEL volumes of all patients
in this study were smaller than the minimum recommended
size (4 cc) to be considered for the traditional fDM [20]. A
second limitation is in the accuracy of the image registra-
tion methods used to align serial ADC images. Significant
tissue shifts were observed in some of our patients after
initial of therapy, mainly because of the reduction in edema
caused by the anti-angiogenic agent, which reduces the
intracranial pressure. In these cases, accurate tissue
matching between different time points can be challenging,
even with non-linear registration.
In conclusion, our study emphasizes the value of ADC
metrics for early assessment of residual tumor in patients
with newly diagnosed GBM being treated with a combi-
nation of therapy that includes bevacizumab. While there
was a rapid decline of ADC percentile values immediately
following onset of therapy in almost all subjects, the ADC
percentile values were lower for the patients who pro-
gressed early. This suggests that tracking the changes in
ADC using serial histogram analysis as shown in Fig. 2
could potentially assist radiologists in monitoring patient
response to therapy that includes bevacizumab. Our results
highlighted the value of ADC10% within the T2L at the
post-RT exam in conjunction with standard clinical factors
in predicting PFS and OS. We hypothesize that this is due
to the anti-angiogenic effect of bevacizumab reducing the
extent of vasogenic edema at this time point and therefore
allowing the observed ADC values to more accurately
reflect the residual tumor burden.
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